Grifols (BME:GRF) Stock Rallies Into Profit Growth and Debt Questions

Grifols stock comes into this earnings day with the wind at its back. The share price closed at €10.36 on 29 July, capping a roughly 16% gain over the past three months. That is the market saying confidence has quietly been rebuilt.

The headline from the release is much simpler. This is a plasma biopharma business that just reported Q2 revenue of €1.874b and group profit of €227m for the first half, with adjusted earnings before interest, tax, depreciation and amortization margins holding in the mid 20s. The key question is whether that earnings power justifies how far the stock has already run.

Is Grifols trading at a rare €10.36 opportunity, or is the discount simply compensation for cash flow and debt risk? Compare the current price against our detailed valuation analysis for Grifols

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): €1,874m vs. €1,891.1m (broadly stable at a slightly lower level)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): €155m vs. €117.1m (up about 32%)
• Basic EPS (Trailing 12 Months to Q2 2026 vs. TTM to Q2 2025): €0.5907 vs. €0.4527 (up about 30%)
• Adjusted EBITDA Margin (Q2 2026 vs. H1 2026): 25.2% vs. 23.9% (Q2 margin above the first-half average)

Prefer clear charts instead of another wall of earnings tables and ratios? See Grifols' full valuation picture laid out in a simple visual dashboard through the company report for Grifols.

Grifols bull case anchored in execution milestones

Bulls argue Grifols is turning a strong plasma portfolio and better operations into higher quality earnings and cash generation. The latest numbers give some support. Biopharma is the clear engine, with H1 growth of 5.4% at constant currency and immunoglobulins up 12.8%. Subcutaneous IG product Xembify grew about 34% in Q2, which lines up with the story of higher value, convenience products gaining share. Group profit for H1 reached €227m and adjusted EBITDA margin was 23.9% in H1, rising to 25.2% in Q2. That points to early traction on margin work and “smart growth” discipline. Free cash flow before M&A improved by about €103m year on year to €91m, and net leverage is around 4.2x with liquidity above €2b. These are tangible steps toward the deleveraging and cash focus bulls want to see.

Grifols bear case tests debt, pricing and risk

Bears focus on debt, pricing pressure and execution risk in plasma sourcing and regulation. The Q2 and H1 print does not clear these concerns. Net leverage around 4.2x keeps balance sheet risk front and center and the company still relies on meaningful debt servicing. China albumin pricing remains a pressure point after a mid 2025 concession. Management only guides to H2 2026 levels being in line with H2 2025, which suggests limited pricing recovery so far. The need to close 29 U.S. donor centers to improve efficiency shows that the plasma network still requires heavy reshaping before it reaches a steady state. On governance and oversight, the ongoing scrutiny in Canada over safety and regulatory questions underlines that reputational and regulatory risk has not fully cleared and could weigh on expansion plans if issues escalate.

After heavy one off items, leverage near 4x and regulatory scrutiny, you may want to review our independent risk analysis for Grifols which shows 3 important warning signs.

Shape Your Next Investing Move

If Grifols' mix of earnings progress and balance sheet questions has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value estimates and watch how the story develops. When you decide to take a position, use the Portfolio Command Center to cut through noise and stay on top of the most important updates to your holdings. For longer term conviction, tap into the Community to see how other investors are thinking about the same risks and opportunities. That way you can spot potential catalysts or red flags early and stay informed about the market.

Seeking Alternatives Beyond Grifols?

Fresh stock ideas can start breaking out while you watch Grifols and other familiar names. Use these curated lists before the momentum gets fully caught by the crowd, and consider them promptly.

• Spot potential breakout compounders early by scanning a curated 515 high quality undiscovered gems that are still under the radar for now but already backed by solid fundamentals.
• Target resilient compounding with a hand picked 439 dividend fortresses that focuses on stability, income and businesses built to keep distributing cash even when sentiment drops.
• Ride structural trends in electricity and data by checking 34 power grid technology and infrastructure stocks that could benefit if grid upgrades and infrastructure momentum move from talk to execution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com